Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
With
Kyowa Kirin Co., Ltd.
AstraZeneca
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of asthma, and presently has reversibility over pre-bronchodilator forced expiratory volume in 1 second (FEV1) of ≥ 20% at screening
Percent of predicted FEV1 ≥ 40% and ≤ 80% at screening
Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000/μg/day fluticasone powder or equivalent
Ongoing asthma symptoms with asthma control questionnaire (ACQ) composite score at screening and baseline ≥ 1.5 points
You may not be if
History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma
History of allergic bronchopulmonary aspergillosis
Respiratory infection within 4 weeks of screening or 1 week of baseline visit
Subject has known history of Crohn's disease
Subject has any other significant concurrent medical condition of laboratory abnormalities, as defined in the study protocol
Subject has previously used any anti-interleukin-17 (IL17) biologic therapy
Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study
Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile
Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)
Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety
Clareo Health | Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility
